Centrose Receives Federal Funding to Fully Automate Drug Discovery Platform

MADISON, WI. January 10, 2008 – Efforts to move CarboConnect™ toward a completely automated process for "sugar enhanced drug discovery" will now benefit from $200,000 of additional funding. Centrose today received official notice that the National Institute of General Medical Sciences (NIGMS) will help fund Centrose's effort aimed at automating CarboConnect. CarboConnect brings together automation, targeted sets of sugars and enhanced biochemistries to rapidly manufacture and screen exciting new drug leads.

To date, the platform has lead to the discovery of a number of drugs having the potential to fight some of the most problematic diseases. Last year, the Company submitted a funding proposal which outlined the importance of CarboConnect in new drug discovery and how complete automation could be used to make the process more versatile.

Early last year, Centrose exclusively licensed a set of drug enhancement technologies and lead compounds from the Wisconsin Alumni Research Foundation (WARF). Since then, Centrose improved the enhancement process by lowering production costs and increasing discovery rates, giving it the trademark name, CarboConnect. CarboConnect is now allowing Centrose to find more leads with less money. Centrose closed its seed round financing last year believing that its first year goals could be reached without additional monies. With this NIGMS funding, it has funds to further advance CarboConnect toward full automation. "This is the fourth federal institute to fund our drug discovery efforts," states Dr. James Prudent the Company's Chief Executive Officer. "We told our investors that we were optimistic about receiving these four grants and now we have delivered".

About Centrose LLC

Centrose, a Madison Wisconsin based biopharmaceutical company, is applying scientific breakthroughs in sugar chemistry to the discovery, development and commercialization of small molecule therapeutics. Centrose employs CarboConnect™ technology for the attachment of any sugar molecule to any compound. Sugars are critical to the regulation of biological processes and pathways in the human body, and play fundamental roles in drug action. Several small-molecule drugs like erythromycin (a commonly used antibiotic) or doxorubicin (a commonly used anticancer) contain sugar linkages. It is the sugar linkages that bestow drug activity. Modifying existing small-molecule drugs with sugars has been shown to improve drug activity. Centrose's proprietary sugar technology enables the rapid enhancement of a wide variety of important drugs in a one-step process with manufacturing scalability. Centrose owns a broad set of patents and patent applications issued and filed by the Wisconsin Alumni Research Foundation and The Sloan Kettering Institute.

Contacts:
James Prudent, Ph.D.
Chief Executive Officer,
Centrose LLC
(608) 209-8933